Global Dermatological Drugs Market 2014-2018
DUBLIN, April 28, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/3ldn2f/global) has announced the addition of the "Global Dermatological Drugs Market 2014-2018" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Biologics are manufactured proteins interfering with the immune process involved in any dermatological disorders. In recent years, the enhanced understanding of the molecular basis underlying dermatological ailment led to the introduction of biological drugs, providing a new effective treatment option for dermatological disorders.
Biologics emphasizes on specific aspects of the immune function that result in any illness. Along with topical treatments, the current market is crowded with biologics for dermatology. Amgen/Wyeth's Enbrel continues to hold its position as market leader amongst biologics; however, Abbott's Humira has increased its share significantly in the past year. The pipeline is also very promising with biologics and several other treatments for mild to moderate conditions. Hence, the Global Dermatological Drugs market is expected to reap large revenues with the increasing use of biologics.
According to the report, one of the main drivers is the increasing global aging population. Aged patients have a greater number of dermatological disorders caused by thinning and loss of elasticity of the epidermis.
Further, the report states that one of the key challenges is the risk of side effects associated with dermatology drugs, which hampers the acceptance of advanced biologic drugs for the treatment of dermatology disorders.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
05. Introduction
06. Market Landscape
07. Market Segmentation by Type
08. Geographical Segmentation
09. Buying Criteria
10. Rate of Incidence and Prevalence
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
18. Key Vendor Analysis
19. Other Reports in this Series
Companies Mentioned:
- AbbVie Inc.
- Actavis plc
- Allergan Inc.
- Almirall SA
- Amgen Inc.
- Astellas Pharma Inc.
- AstraZeneca plc
- Bayer AG
- Bristol Myers Squibb Co.
- Celgene Corp.
- Eisai Co. Ltd.
- Eli Lilly and Co.
- Galderma S.A.
- Genentech Inc.
- Incyte Corp.
- Isotechnika Inc.
- Johnson & Johnson Ltd.
- LEO Pharma A/S
- Merck & Co. Inc.
- Mylan Pharmaceuticals Inc.
- Novartis AG
- Pfizer Inc.
- Stiefel Laboratories Inc.
- UCB SA.
- Valeant Pharmaceuticals International Inc.
For more information visit http://www.researchandmarkets.com/research/3ldn2f/global
Media Contact: Laura Wood, +353-1-481-1716, [email protected]
SOURCE Research and Markets
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article